- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap plasmid (retina-validated serotype AAV-RC plasmid) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi's AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) capsid protein.
You can produce AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) particle in 293T cell line in high titer using GeneMedi's AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection., with potential applications in retina gene therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.
Go to AAV
vector system
>>
Manual
Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-RC05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid (Amp resistance) Size：5ug | Academic | 1956 | ||
| P-RC05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid (Amp resistance) Size：5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-RC05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid (Amp resistance) Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid (Amp resistance) Size：≥10mg |
All | |||
| P-RC05-Kan | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid (Kan resistance) Size：≥10mg |
All | |||
| P-PK05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Vector
System (Amp resistance)
1. AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug |
Academic | 3216 | ||
| P-PK05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Vector
System (Amp resistance)
1. AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-PK05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Vector
System (Amp resistance)
1. AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK05 | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Vector
System (Amp resistance)
1. AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK05-Kan | AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Vector
System(Kan resistance)
1. AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap Plasmid(Kan resistance), ≥10mg 2. AAV Helper Plasmid(Kan resistance), ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression | Science | 2022/8/4 |
| 3’untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein | European Heart Journal | 2021/5/15 |
| Faecalibacterium Prausnitzii Attenuates CKD via Butyrate-Renal GPR43 Axis | CIRCULATION RESEARCH | 2022/9/27 |
| Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms | Science Translational Medicine | 2022/4/13 |
| SIRT3 Acts As a Negative Regulator of Autophagy Dictating Hepatocyte Susceptibility to Lipotoxicity | HEPATOLOGY | 2017/7/20 |
| TNFR2 Stimulation Promotes Mitochondrial Fusion via Stat3- and NF-kB–Dependent Activation of OPA1 Expression | CIRCULATION RESEARCH | 2017/8/3 |
| The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma | Nature Communications | 2022/3/16 |
| VPS41-mediated incomplete autophagy aggravates cadmium-induced apoptosis in mouse hepatocytes | Journal of Hazardous Materials | 2023/8/7 |
| NR3C1/Glucocorticoid receptor activation promotes pancreatic β-cell autophagy overload in response to glucolipotoxicity | Autophagy | 2023/4/11 |
| Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1 | JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023/5/19 |
Validation data
.webp)
Figure. Selected transduction results of AAV2 variant(Y444F) vector system in mouse retina.
Virus and titer: AAV2 variant(Y444F) vector system, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
